Press coverage about BioDelivery Sciences International (NASDAQ:BDSI) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioDelivery Sciences International earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 46.5220374051273 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- ETFs with exposure to BioDelivery Sciences International, Inc. : August 7, 2017 (finance.yahoo.com)
- Needle Tilting Mid-Session For BioDelivery Sciences International Inc (BDSI) - Stock Press Daily (stockpressdaily.com)
- $BDSI Stock Quote Alert for BioDelivery Sciences International Inc. (NASDAQ:BDSI) From our Stock News Alerts App (4-traders.com)
- PRA Health Sciences, Inc. (PRAH) registers a change of -1.01% while BioDelivery Sciences International, Inc. (BDSI … - Stocks Gallery (stocksgallery.com)
- Technical Reports on Biotech Equities — BioDelivery Sciences, BioLine Rx, Benitec Biopharma, and Soligenix - Markets Insider (markets.businessinsider.com)
Several research analysts have recently commented on BDSI shares. Cantor Fitzgerald upgraded BioDelivery Sciences International from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $3.00 to $4.00 in a report on Tuesday, May 16th. FBR & Co set a $4.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Tuesday, May 16th. Roth Capital set a $5.00 price objective on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Tuesday, May 16th. ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Finally, HC Wainwright started coverage on BioDelivery Sciences International in a report on Friday, May 26th. They issued a “buy” rating and a $4.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $4.00.
BioDelivery Sciences International (BDSI) traded up 0.806% during mid-day trading on Tuesday, hitting $3.125. The company had a trading volume of 107,192 shares. BioDelivery Sciences International has a 1-year low of $1.50 and a 1-year high of $3.60. The stock has a 50 day moving average price of $2.90 and a 200-day moving average price of $2.19. The stock’s market capitalization is $172.89 million.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Monday, May 15th. The specialty pharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.49. The firm had revenue of $29.48 million for the quarter, compared to analysts’ expectations of $27.07 million. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%. On average, analysts forecast that BioDelivery Sciences International will post $0.14 earnings per share for the current year.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
